NPCE vs. TNDM, LQDA, INMD, CDRE, BLFS, KMTS, MDXG, ESTA, FNA, and EYE
Should you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include Tandem Diabetes Care (TNDM), Liquidia (LQDA), InMode (INMD), Cadre (CDRE), BioLife Solutions (BLFS), Kestra Medical Technologies (KMTS), MiMedx Group (MDXG), Establishment Labs (ESTA), Paragon 28 (FNA), and National Vision (EYE). These companies are all part of the "medical equipment" industry.
NeuroPace vs.
NeuroPace (NASDAQ:NPCE) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, community ranking, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.
78.8% of NeuroPace shares are held by institutional investors. 22.2% of NeuroPace shares are held by company insiders. Comparatively, 2.2% of Tandem Diabetes Care shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Tandem Diabetes Care has a net margin of -14.84% compared to NeuroPace's net margin of -36.74%. Tandem Diabetes Care's return on equity of -44.19% beat NeuroPace's return on equity.
Tandem Diabetes Care received 556 more outperform votes than NeuroPace when rated by MarketBeat users. Likewise, 61.02% of users gave Tandem Diabetes Care an outperform vote while only 60.78% of users gave NeuroPace an outperform vote.
NeuroPace has a beta of 2.06, indicating that its share price is 106% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
NeuroPace presently has a consensus price target of $15.20, indicating a potential upside of 27.51%. Tandem Diabetes Care has a consensus price target of $45.38, indicating a potential upside of 137.01%. Given Tandem Diabetes Care's higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than NeuroPace.
NeuroPace has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks.
In the previous week, Tandem Diabetes Care had 2 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for Tandem Diabetes Care and 3 mentions for NeuroPace. Tandem Diabetes Care's average media sentiment score of 1.23 beat NeuroPace's score of 0.30 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.
Summary
Tandem Diabetes Care beats NeuroPace on 11 of the 18 factors compared between the two stocks.
Get NeuroPace News Delivered to You Automatically
Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroPace Competitors List
Related Companies and Tools
This page (NASDAQ:NPCE) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy NPCE Stock Free NPCE Stock Alerts